Oral delivery of anticancer drugs II: The prodrug strategy

Drug Discovery Today

Volumn 18, Issue 1-2, 2013, Pages 93-98

  Mazzaferro, Silvia ^a   Bouchemal, Kawthar ^a   Ponchel, Gilles ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2' OXOPROPYL) 5 FLUOROURACIL; 5 ETHYNYLURACIL; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; AURANTIIN; CAMPTOTHECIN; CAPECITABINE; DOCETAXEL; DOXIFLURIDINE; EMITEFUR; FIRTECAN; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; GALOCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; LURTOTECAN; OFU 001; ORZEL; OXALIPLATIN; PACLITAXEL; PICOPLATIN; PLATINUM AMMINE CYCLOHEXYLAMINE DICHLORIDE; POLYMER; PRODRUG; QUERCETIN; RUBITECAN; SATRAPLATIN; TOPOTECAN; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER SURVIVAL; CARDIOTOXICITY; CELL CYCLE ARREST; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COLITIS; COLON CANCER; COLORECTAL CANCER; CONTINUOUS INFUSION; DEPRESSION; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME ACTIVITY; FATIGUE; FEBRILE NEUTROPENIA; FOOD AND DRUG ADMINISTRATION; FOOT PAIN; GASTROINTESTINAL MUCOSA; GASTROINTESTINAL TOXICITY; GASTROINTESTINAL TRACT; HAND FOOT AND MOUTH DISEASE; HAND FOOT SYNDROME; HAND PAIN; HEAD AND NECK CANCER; HEMORRHAGIC CYSTITIS; HUMAN; IN VIVO STUDY; INFECTION; INTESTINE TOXICITY; LETHARGY; LUNG NON SMALL CELL CANCER; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; ORAL DRUG ADMINISTRATION; ORAL MUCOSITIS; OVARY CANCER; PANCREAS CANCER; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POSTOPERATIVE CARE; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; RHABDOMYOSARCOMA; SINGLE DRUG DOSE; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; DRUG DESIGN; HUMANS; INTESTINAL ABSORPTION; NEOPLASMS; PERMEABILITY; PRODRUGS; SOLUBILITY;

EID: 84871920020     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2012.08.006     Document Type: Review

References (90)

1. A. Albert Chemical aspects of selective toxicity Nature 182 1958 421 422
2. B. Testa Prodrug research: futile or fertile? Biochem. Pharmacol. 68 2004 2097 2106
3. Y. Singh Recent trends in targeted anticancer prodrug and conjugate design Curr. Med. Chem. 15 2008 1802 1826
4. S.K. Sharma, and K.D. Bagshawe Antibody-directed enzyme prodrug therapy (ADEPT) for cancer Macromolecular Anticancer Therapeutics (Cancer Drug Discovery and Development) Vol. 4 2010 Springer pp. 393-406
5. L. Tietze, and B. Krewer Antibody-directed enzyme prodrug therapy: a promising approach for a selective treatment of cancer based on prodrugs and monoclonal antibodies Chem. Biol. Drug Des. 74 2009 205 211
6. G.F. Rowland Suppression of tumor growth in mice by a drug-antibody conjugate using a novel approach to linkage Nature 255 1975 487 488
7. D. Fleisher Improved oral drug delivery: solubility limitations overcome by the use of prodrugs Adv. Drug Deliv. Rev. 19 1996 115 130
8. C. Heidelberger Fluorinated pyrimidines, a new class of tumour-inhibitory compounds Nature 179 1957 663 666
9. S. Sharma, and L.B. Saltz Oral chemotherapeutic agents for colorectal cancer Oncologist 5 2000 99 107
10. C. Eng Oral fluoropyrimidine treatment of colorectal cancer Clin. Colorectal Cancer 1 2001 95 103
11. M. Malet-Martino, and R. Martino Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review Oncologist 7 2002 288 323
12. A. Grothey, and M.P. Goetz Oxaliplatin plus oral fluoropyrimidines in colorectal cancer Clin. Colorectal Cancer 4 2004 S37 S42
13. W. Gradishar, and E. Vokes Review: 5-fluorouracil cardiotoxicity: a critical review Ann. Oncol. 1 1990 409 414
14. D. Cunningham New options for outpatient chemotherapy-the role of oral fluoropyrimidines Cancer Treat. Rev. 27 2001 211 220
15. R. Fraile Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion Cancer Res. 40 1980 2223 2228
16. R.B. Diasio The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology Oncology-Huntington 12 1998 23 27
17. E. Bajetta A pilot safety study of capecitabine, a new oral fluoropyrimidine, in patients with advanced neoplastic disease Tumori 82 1996 450 452
18. M. Haraguchi Angiogenic activity of enzymes Nature 368 1994 198
19. D. Ho Oral uracil and ftorafur plus leucovorin: pharmacokinetics and toxicity in patients with metastatic cancer Cancer Chemother. Pharmacol. 46 2000 351 356
20. E. Lamont, and R.L. Schilsky The oral fluoropyrimidines in cancer chemotherapy Clin. Cancer Res. 5 1999 2289 2296
21. M.S. Braun, and M.T. Seymour Review: balancing the efficacy and toxicity of chemotherapy in colorectal cancer Ther. Adv. Med. Oncol. 3 2011 43 52
22. M. Ferguson The role of pro-drug therapy in the treatment of cancer Drug Resist. Updates 4 2001 225 232
23. 14C-labelled drug Invest. New Drugs 17 1999 49 56
24. B. Reigner Clinical pharmacokinetics of capecitabine Clin. Pharmacokinet. 40 2001 85 104
25. M. Miwa Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue Eur. J. Cancer 34 1998 1274 1281
26. H. Ishitsuka Capecitabine: an orally available fluoropyrimidine with tumor selective activity Invest. New Drugs 18 1995 343 354
27. G. Koukourakis Efficacy of the oral fluorouracil pro-drug capecitabine in cancer treatment: a review Molecules 13 2008 1897 1922
28. S.E. Mikhail Safety of capecitabine: a review Expert Opin. Drug Saf. 9 2010 831 841
29. N. Meropol Oral fluoropyrimidines in the treatment of colorectal cancer Eur. J. Cancer 34 1998 1509 1513
30. S. Fujii Effect of coadministration of uracil or cytosine on the anti-tumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents Gann 70 1979 209 214
31. M. El-Sayed Transepithelial transport of poly(amidoamine) dendrimers across Caco-2 cell monolayers J. Control. Release 8 2002 355 365
32. F. Tanaka Advantage of post-operative oral administration of UFT (Tegafur and Uracil) for completely resected p-stage I-IIIa non-small cell lung cancer (NSCLC) 1 Eur. J. Cardio-Thorac. 14 1998 256 262
33. R.A. Brito Fluoropyrimidines: a critical evaluation Oncology 57 2000 2 8
34. K. Ohyama Antineoplastic effect of UFT therapy (uracil-FT-207 combination therapy) on experimental pancreatic cancer transplanted in the pancreas and subcutaneous region Gan To Kagaku Ryoho/Cancer Chemother. 9 1982 2168 2174
35. T. Fukui Clinical study on the enhancement of drug delivery into tumor tissue by using UFT Jpn. J. Cancer Chemother. 7 1980 2124 2129
36. F. Tanaka UFT and S-1 for treatment of primary lung cancer Gen. Thorac. Cardiovasc. Surg. 58 2010 3 13
37. L. Saltz A fixed-ratio combination of uracil and ftorafur (UFT) with low dose leucovorin. An active oral regimen for advanced colorectal cancer Cancer 75 1995 782 785
38. A. De la Torre Phase II study of radiochemotherapy with UFT and low-dose oral leucovorin in patients with unresectable rectal cancer Int. J. Radiat. Oncol. 45 1999 629 634
39. M. Borner Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal Eur. J. Cancer 38 2002 349 358
40. K. Shirao Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with Advanced Colorectal Cancer: Joint United States and Japan Study of UFT/LV J. Clin. Oncol. 22 2004 3466 3474
41. T. Shirasaka Conceptual changes in cancer chemotherapy: from an oral fluoropyrimidine prodrug, UFT, to a novel oral fluoropyrimidine prodrug, S-1, and low-dose FP therapy in Japan Invest. New Drugs 18 2000 315 329
42. P. Schoffski Safety, toxicity and antitumor efficacy of the modulated oral fluoropyrimidine derivative S-1 in patients with metastatic colorectal cancer: preliminary results of an early phase II study Clin. Cancer Res. 5 Suppl. 1999 S3772
43. K. Nakamura Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer Br. J. Cancer 94 2006 1575 1579
44. K. Nakamura Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer Br. J. Cancer 92 2005 2134 2139
45. S. Sakuramoto Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine N. Engl. J. Med. 357 2007 1810 1820
46. Y. Sakata Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients Eur. J. Cancer 34 1998 1715 1720
47. M. Kawahara Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer Br. J. Cancer 85 2001 939 943
48. S. Cohen Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer Clin. Cancer Res. 8 2002 2116 2122
49. H. Iwamoto Metronomic S-1 chemotherapy and vandetanib: an efficacious and nontoxic treatment for hepatocellular carcinoma Neoplasia 13 2011 187 197
50. S. Hijioka Eight-year survival after advanced gastric cancer treated with S-1 followed by surgery World J. Gastroenterol. 16 2010 2824 2827
51. D. Yamamoto Efficacy of S-1 in patients with capecitabine-resistant breast cancer-Japan Breast Cancer Research Network (JBCRN) 04-1 Trial Anticancer Res. 30 2010 3827 3831
52. F. Hara Efficacy and safety of S-1 in patients with metastatic breast cancer: retrospective review in a single institution Oncology 79 2010 273 277
53. J. Seong Preoperative chemoradiotherapy with oral doxifluridine plus low-dose oral leucovorin in unresectable primary rectal cancer Int. J. Radiat. Oncol. 50 2001 435 439
54. Y. Ninomiya Comparative antitumor activity and intestinal toxicity of 5′-deoxy-5-fluorouridine and its prodrug trimethoxybenzoyl-5′-deoxy- 5-fluorocytidine Cancer Sci. 81 1990 188 195
55. N.J. Wheate The status of platinum anticancer drugs in the clinic and in clinical trials Dalton Trans. 39 2010 8097 8340
56. H. Choy Current status and future prospects for satraplatin, an oral platinum analogue Clin. Cancer Res. 14 2008 1633 1638
57. L. Kelland The resurgence of platinum-based cancer chemotherapy Nat. Rev. Cancer 7 2007 573 584
58. H. Ringsdorf Structure and properties of pharmacologically active polymers J. Polym. Sci. Polym. Symp. 51 1975 135 153
59. R. Tong, and J. Cheng Anticancer polymeric nanomedicines Polym. Rev. 47 2007 345 381
60. R.B. Greenwald Effective drug delivery by PEGylated drug conjugates Adv. Drug Deliv. Rev. 55 2003 217 250
61. R. Greenwald PEG drugs: an overview J. Control. Release 74 2001 159 171
62. H. Maeda Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo Bioconjug. Chem. 3 1992 351 362
63. G. Pasut, and F. Veronese Polymer-drug conjugation, recent achievements and general strategies Prog. Polym. Sci. 32 2007 933 961
64. M.J. Vicent, and R. Duncan Polymer conjugates: nanosized medicines for treating cancer Trends Biotechnol. 24 2006 39 47
65. M. Skwarczynski Paclitaxel prodrugs: toward smarter delivery of anticancer agents J. Med. Chem. 49 2006 7253 7269
66. J.S. Choi, and B.W. Jo Enhanced paclitaxel bioavailability after oral administration of pegylated paclitaxel prodrug for oral delivery in rats Int. J. Pharm. 280 2004 221 227
67. J.S. Choi Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin Eur. J. Pharm. Biopharm. 57 2004 313 318
68. J.S. Choi, and H.K. Han Enhanced oral exposure of diltiazem by the concomitant use of naringin in rats Int. J. Pharm. 305 2005 122 128
69. E. Lee In vivo antitumor effects of chitosan-conjugated docetaxel after oral administration J. Control. Release 140 2009 79 85
70. E. Lee Conjugated chitosan as a novel platform for oral delivery of paclitaxel J. Med. Chem. 51 2008 6442 6449
71. H. Gelderblom Oral topoisomerase 1 inhibitors in adult patients: present and future Invest. New Drugs 17 1999 401 415
72. I. Kuppens Topoisomerase I inhibitors in the treatment of gastrointestinal cancer: from intravenous to oral administration Clin. Colorectal Cancer 4 2004 163 180
73. R. Mathijssen Clinical pharmacokinetics and metabolism of irinotecan (CPT-11) Clin. Cancer Res. 7 2001 2182 2194
74. O. Soepenberg Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors Clin. Cancer Res. 11 2005 1504 1511
75. O. Soepenberg Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors J. Clin. Oncol. 23 2005 889 898
76. A. Pappo Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: The Children's Oncology Group J. Clin. Oncol. 25 2007 362 369
77. E. Bajetta Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma Cancer 100 2004 279 287
78. R. Drengler Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors J. Clin. Oncol. 17 1999 685 696
79. H. Pitot A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumor Cancer Chemother. Pharmacol. 58 2006 165 172
80. L. Wagner Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group Phase I Consortium Study Pediatr. Blood Cancer 54 2010 538 545
81. J.W. Clark Rubitecan Expert Opin. Investig. Drugs 15 2006 71 79
82. P. Schöffski Clinical phase II study and pharmacological evaluation of rubitecan in non-pretreated patients with metastatic colorectal cancer-significant effect of food intake on the bioavailability of the oral camptothecin analogue Eur. J. Cancer 38 2002 807 813
83. F. Caponigro Phase II study of rubitecan in recurrent or metastatic head and neck cancer Cancer Chemother. Pharmacol. 62 2008 209 214
84. S. Baka A phase II trial with RFS2000 (rubitecan) in patients with advanced non-small cell lung cancer Eur. J. Cancer 41 2005 1547 1550
85. H. Patel Phase II study of rubitecan, an oral camptothecin in patients with advanced colorectal cancer who have failed previous 5-fluorouracil based chemotherapy Invest. New Drugs 24 2006 359 363
86. H. Burris III Phase II trial of oral rubitecan in previously treated pancreatic cancer patients Oncologist 10 2005 183 190
87. K. Tedesco A phase I study of concurrent 9-nitro-20 (s)-camptothecin (9NC/orathecin) and radiation therapy in the treatment of locally advanced adenocarcinoma of the pancreas Radiother. Oncol. 76 2005 54 58
88. P. Fracasso Phase I study of rubitecan and gemcitabine in patients with advanced malignancies Ann. Oncol. 13 2002 1819 1825
89. B. Conley Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors Clin. Cancer Res. 4 1998 629 634
90. M. Edelman Clinical and pharmacologic study of tributyrin: an oral butyrate prodrug Cancer Chemother. Pharmacol. 51 2003 439 444